– Senior leader with proven track record of executing business development and licensing transactions totaling $5 billion at multinational pharmaceutical and biotechnology companies NEW YORK, Nov. 3, 2023 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or…
